BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Frequently asked questions
What sector does BriaCell Therapeutics Corp. Warrant (BCTXZ) operate in?
BriaCell Therapeutics Corp. Warrant belongs to the Other sector and operates in the industry.
What is BriaCell Therapeutics Corp. Warrant (BCTXZ) current stock price?
As of the latest data, BriaCell Therapeutics Corp. Warrant stock price is $0.11, with a previous close of $0.11.
What is BriaCell Therapeutics Corp. Warrant (BCTXZ) current market capitalization?
BriaCell Therapeutics Corp. Warrant market cap is approximately 797.55 thousand.
What is BriaCell Therapeutics Corp. Warrant (BCTXZ) EBITDA?
BriaCell Therapeutics Corp. Warrant EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.17 million.
Does BriaCell Therapeutics Corp. Warrant (BCTXZ) pay dividends?
No. BriaCell Therapeutics Corp. Warrant does not pay a dividend.
What is BriaCell Therapeutics Corp. Warrant (BCTXZ) beta (volatility) score?
BriaCell Therapeutics Corp. Warrant has a beta of 1.517, suggesting it is more volatile than the market.
